Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases
Xin Lin,1– 3,* Yali Zhou,3– 5,* Kangjia Lv,3– 5,* Wenjie Wu,1,2 Chong Chen3– 5 1Shengli Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou, Fujian Province, People’s Republic of China; 2Department of Ophthalmology, Fujian Prov...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-07-01
|
| Series: | International Journal of Nanomedicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/nanomedicine-based-ophthalmic-drug-delivery-systems-for-the-treatment--peer-reviewed-fulltext-article-IJN |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849303964812574720 |
|---|---|
| author | Lin X Zhou Y Lv K Wu W Chen C |
| author_facet | Lin X Zhou Y Lv K Wu W Chen C |
| author_sort | Lin X |
| collection | DOAJ |
| description | Xin Lin,1– 3,&ast; Yali Zhou,3– 5,&ast; Kangjia Lv,3– 5,&ast; Wenjie Wu,1,2 Chong Chen3– 5 1Shengli Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou, Fujian Province, People’s Republic of China; 2Department of Ophthalmology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian Province, People’s Republic of China; 3Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai General Hospital, Shanghai, People’s Republic of China; 4Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 5National Clinical Research Center for Eye Diseases, Shanghai General Hospital, Shanghai, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Wenjie Wu, Department of Ophthalmology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, 134 East Street, Fuzhou, Fujian Province, 350000, People’s Republic of China, Tel/Fax +86 8821 7110, Email wenjie_wu@foxmail.com Chong Chen, Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai, 200080, People’s Republic of China, Tel +8615802167095, Email chong.chen1@shgh.cnAbstract: Ocular diseases affect over 2.2 billion people globally, imposing a significant socioeconomic burden, with annual productivity losses estimated at US&dollar;411 billion. Conventional drug delivery methods—topical, local injection, and systemic administration—face challenges such as low bioavailability (< 5%), rapid clearance, and physiological barriers like the cornea and blood-retinal barrier (BRB). Nanomedicine offers promising solutions by enhancing drug bioavailability, prolonging release, and enabling targeted delivery. This review explores nanomedicine-based ophthalmic drug delivery systems, including organic nanomaterials (eg, liposomes, polymer micelles, dendrimers), inorganic nanomaterials (eg, metal nanoparticles, quantum dots), and biological components (eg, exosomes). These systems improve drug penetration, reduce administration frequency, and minimize toxicity, addressing conditions like dry eye disease, keratitis, glaucoma, uveitis, age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vascular occlusion (RVO). For instance, Ocular Therapeutix (OTX)-TP, a sustained-release intracanalicular implant combining poly (ethylene glycol)-based hydrogel with travoprost-loaded poly (lactic acid) microspheres, has shown therapeutic efficacy lasting up to three months in the management of glaucoma and ocular hypertension in Phase III clinical trial. Additionally, a liposomal formulation of verteporfin, approved for the treatment of neovascular AMD, administered intravenously and activated by laser photodynamic therapy, demonstrates a durable response, with a marked reduction in treatment frequency from an average of 3.5 sessions in the first year to only 0.1 by the fifth year post-diagnosis. Despite these advantages, challenges such as manufacturing costs, potential toxicity, and limited clinical translation persist. Future advancements in nanomedicine hold potential for personalized, non-invasive ocular therapies, revolutionizing ophthalmology.Keywords: nanomedicine, ophthalmic drug delivery, ocular diseases, physiological barriers, targeted delivery |
| format | Article |
| id | doaj-art-8e937f5eb8b643beaf77421b9b3e7329 |
| institution | Kabale University |
| issn | 1178-2013 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nanomedicine |
| spelling | doaj-art-8e937f5eb8b643beaf77421b9b3e73292025-08-20T03:55:53ZengDove Medical PressInternational Journal of Nanomedicine1178-20132025-07-01Volume 20Issue 192219249105000Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular DiseasesLin X0Zhou Y1Lv K2Wu WChen C3OphthalmologyDepartment of OphthalmologyDepartment of OphthalmologyDepartment of OphthalmologyXin Lin,1– 3,&ast; Yali Zhou,3– 5,&ast; Kangjia Lv,3– 5,&ast; Wenjie Wu,1,2 Chong Chen3– 5 1Shengli Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou, Fujian Province, People’s Republic of China; 2Department of Ophthalmology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian Province, People’s Republic of China; 3Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai General Hospital, Shanghai, People’s Republic of China; 4Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 5National Clinical Research Center for Eye Diseases, Shanghai General Hospital, Shanghai, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Wenjie Wu, Department of Ophthalmology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, 134 East Street, Fuzhou, Fujian Province, 350000, People’s Republic of China, Tel/Fax +86 8821 7110, Email wenjie_wu@foxmail.com Chong Chen, Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai, 200080, People’s Republic of China, Tel +8615802167095, Email chong.chen1@shgh.cnAbstract: Ocular diseases affect over 2.2 billion people globally, imposing a significant socioeconomic burden, with annual productivity losses estimated at US&dollar;411 billion. Conventional drug delivery methods—topical, local injection, and systemic administration—face challenges such as low bioavailability (< 5%), rapid clearance, and physiological barriers like the cornea and blood-retinal barrier (BRB). Nanomedicine offers promising solutions by enhancing drug bioavailability, prolonging release, and enabling targeted delivery. This review explores nanomedicine-based ophthalmic drug delivery systems, including organic nanomaterials (eg, liposomes, polymer micelles, dendrimers), inorganic nanomaterials (eg, metal nanoparticles, quantum dots), and biological components (eg, exosomes). These systems improve drug penetration, reduce administration frequency, and minimize toxicity, addressing conditions like dry eye disease, keratitis, glaucoma, uveitis, age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vascular occlusion (RVO). For instance, Ocular Therapeutix (OTX)-TP, a sustained-release intracanalicular implant combining poly (ethylene glycol)-based hydrogel with travoprost-loaded poly (lactic acid) microspheres, has shown therapeutic efficacy lasting up to three months in the management of glaucoma and ocular hypertension in Phase III clinical trial. Additionally, a liposomal formulation of verteporfin, approved for the treatment of neovascular AMD, administered intravenously and activated by laser photodynamic therapy, demonstrates a durable response, with a marked reduction in treatment frequency from an average of 3.5 sessions in the first year to only 0.1 by the fifth year post-diagnosis. Despite these advantages, challenges such as manufacturing costs, potential toxicity, and limited clinical translation persist. Future advancements in nanomedicine hold potential for personalized, non-invasive ocular therapies, revolutionizing ophthalmology.Keywords: nanomedicine, ophthalmic drug delivery, ocular diseases, physiological barriers, targeted deliveryhttps://www.dovepress.com/nanomedicine-based-ophthalmic-drug-delivery-systems-for-the-treatment--peer-reviewed-fulltext-article-IJNNanomedicineophthalmic drug deliveryocular diseasesphysiological barrierstargeted delivery |
| spellingShingle | Lin X Zhou Y Lv K Wu W Chen C Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases International Journal of Nanomedicine Nanomedicine ophthalmic drug delivery ocular diseases physiological barriers targeted delivery |
| title | Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases |
| title_full | Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases |
| title_fullStr | Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases |
| title_full_unstemmed | Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases |
| title_short | Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases |
| title_sort | nanomedicine based ophthalmic drug delivery systems for the treatment of ocular diseases |
| topic | Nanomedicine ophthalmic drug delivery ocular diseases physiological barriers targeted delivery |
| url | https://www.dovepress.com/nanomedicine-based-ophthalmic-drug-delivery-systems-for-the-treatment--peer-reviewed-fulltext-article-IJN |
| work_keys_str_mv | AT linx nanomedicinebasedophthalmicdrugdeliverysystemsforthetreatmentofoculardiseases AT zhouy nanomedicinebasedophthalmicdrugdeliverysystemsforthetreatmentofoculardiseases AT lvk nanomedicinebasedophthalmicdrugdeliverysystemsforthetreatmentofoculardiseases AT wuw nanomedicinebasedophthalmicdrugdeliverysystemsforthetreatmentofoculardiseases AT chenc nanomedicinebasedophthalmicdrugdeliverysystemsforthetreatmentofoculardiseases |